Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Chugai Sues Alexion Japan over Soliris Successor ALXN1210 after US
December 6, 2018
- Amicus Aims to Expand Rare and Intractable Disease Pipeline in Japan
December 6, 2018
- Shareholders Give Blessing to £46 Billion Shire Pact as Weber Touts US Foothold
December 6, 2018
- Takeda Shareholders OK £46 Billion Shire Takeover
December 5, 2018
- Hemlibra Approved in Taiwan for Treatment of Hemophilia A with Inhibitors: Chugai
December 5, 2018
- Gilteritinib Shows High Response Rate in Previously Untreated AML Patients in PI: Astellas
December 5, 2018
- Elmed Eisai to Be Renamed “Elmed”, Move Headquarters to Toyama
December 5, 2018
- Takeda Family Member Comes Forward for Final Appeal to Veto Shire Deal, but Admits Uphill Battle
December 4, 2018
- Takeda Inks US$3.7 Billion Loan Accord with JBIC
December 4, 2018
- Ninlaro Shows 39% Improvement in PFS in Post-Transplant Multiple Myeloma Patients: Takeda
December 4, 2018
- Astellas Launches Sakigake-Designated AML Drug Xospata
December 4, 2018
- Fujifilm Toyama Chemical Licenses Cancer “Theragnostic” Agent to Novartis Subsidiary
December 4, 2018
- MSD Japan Chief Voices High Hopes for Keytruda Label Expansions
December 3, 2018
- With Current R&D Model Reaching Its Limit, Industry Going Digital to Boost Efficiency: Astellas Chairman
December 3, 2018
- Lilly Launches Breast Cancer Drug Verzenio
December 3, 2018
- AbbVie Files Maviret for Pediatric Use for Age 12 and Older
December 3, 2018
- Olympus to Launch Japan Clinical Study of Regenerative Medicine Product for Traumatic Cartilage Defects
December 3, 2018
- ADHD Treatments to Reap 50% Growth in 2026, Despite Shrinking CNS Market: Fuji Keizai
December 3, 2018
- US FDA Approves Astellas’ AML Treatment Xospata
November 30, 2018
- Celgene Files Otezla for Additional Indication of Oral Ulcers due to Behcet’s Disease
November 30, 2018
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…